Quintiles, Eisai to co-develop cancer drugs
Quintiles Transnational and Eisai formed a partnership to develop six cancer drugs under Eisai's pipeline for an undisclosed amount. Quintiles' NovaQuest unit will co-fund 11 midstage trials of the experimental drugs.
American City Business Journals | 10/30
This story published in BIO SmartBrief on 11/02/2009
More from SmartBrief:
GSK to develop biotech cancer drugs with SuperGen
Monday, November 2, 2009
Forma partners with Novartis in cancer-drug development
Thursday, July 30, 2009
Amgen to use ImmunoGen technology for cancer treatments
Thursday, September 17, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|